In a phase 3 trial of 568 adults with Crohn's disease and complex perianal fistulas, darvadstrocel did not improve combined remission at week 24 vs placebo (48.8% vs 46.3%; P=.571); key secondary endpoints also showed no difference.
RCTn = 568
Colombel et al. Darvadstrocel in Patients With Crohn's Disease With Complex Perianal Fistulas: The ADMIRE CD II Phase 3 Randomized Trial